

31 October 2022

Cizzle Biotechnology Holdings Plc

("Cizzle Biotechnology" or the "Company")

Total Voting Rights

Cizzle Biotechnology, the UK based diagnostics developer, makes the following announcement in accordance with Rule 5.6.1 of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

As of 31 October 2022, the Company's issued ordinary share capital consists of 339,803,549 ordinary shares of 0.01 pence each, each with one voting right. The Company holds no ordinary shares in Treasury. Therefore, the Company's total number of ordinary shares and voting rights is 339,803,549 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Cizzle Biotechnology Holdings plc
Allan Syms (Executive Chairman)

Via IFC Advisory

Allenby Capital Limited
John Depasquale
Alex Brearley

+44(0) 20 33285656

Novum Securities Limited
Colin Rowbury
Jon Bellis

+44(0) 20 7399 9400

IFC Advisory Limited
Tim Metcalfe
Florence Chandler

+44(0) 20 3934 6630
cizzle@investor-focus.co.uk

Notes to Editors:

About Cizzle Biotechnology

Cizzle Biotechnology is developing a blood test for the early detection of lung cancer. Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability

to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.

For more information, please see <https://cizzlebiotechnology.com>

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.